OBJECTIVES: To compare the dose-volume data of three-dimensional conformal proton therapy (3DCPT) versus intensity-modulated radiotherapy (IMRT) for a paranasal sinus malignancy. METHODS: 3DCPT and IMRT plans were created for a T4N0 maxillary sinus carcinoma. RESULTS: The target volume dose distributions were comparable for 3DCPT and IMRT. The mean and integral doses for all normal tissues were lower for 3DCPT. The maximum doses for both plans to the ipsilateral optic nerve/retina/lens, temporal lobe, pituitary, and brain exceeded tolerance doses. The contralateral parotid, lacrimal gland, and lens were avoided with 3DCPT. Neither 3DCPT nor IMRT exceeded the maximal tolerated dose for the brainstem, optic chiasm, contralateral temporal lobe, parotid, or lacrimal gland. CONCLUSIONS: Both 3DCPT and IMRT sufficiently covered the target volume(s). Although 3DCPT reduced the mean and integral dose to all of the normal tissues, both 3DCPT and IMRT irradiated the ipsilateral optic structures beyond acceptable tolerance doses.
OBJECTIVES: To compare the dose-volume data of three-dimensional conformal proton therapy (3DCPT) versus intensity-modulated radiotherapy (IMRT) for a paranasal sinus malignancy. METHODS: 3DCPT and IMRT plans were created for a T4N0 maxillary sinus carcinoma. RESULTS: The target volume dose distributions were comparable for 3DCPT and IMRT. The mean and integral doses for all normal tissues were lower for 3DCPT. The maximum doses for both plans to the ipsilateral optic nerve/retina/lens, temporal lobe, pituitary, and brain exceeded tolerance doses. The contralateral parotid, lacrimal gland, and lens were avoided with 3DCPT. Neither 3DCPT nor IMRT exceeded the maximal tolerated dose for the brainstem, optic chiasm, contralateral temporal lobe, parotid, or lacrimal gland. CONCLUSIONS: Both 3DCPT and IMRT sufficiently covered the target volume(s). Although 3DCPT reduced the mean and integral dose to all of the normal tissues, both 3DCPT and IMRT irradiated the ipsilateral optic structures beyond acceptable tolerance doses.
Authors: Alexandra D Jensen; Anna V Nikoghosyan; Christine Windemuth-Kieselbach; Jürgen Debus; Marc W Münter Journal: BMC Cancer Date: 2011-05-22 Impact factor: 4.430
Authors: Alexandra D Jensen; Anna V Nikoghosyan; Swantje Ecker; Malte Ellerbrock; Jürgen Debus; Marc W Münter Journal: Radiat Oncol Date: 2011-04-05 Impact factor: 3.481
Authors: Jidapa Bridhikitti; Jason K Viehman; W Scott Harmsen; Adam C Amundson; Satomi Shiraishi; Daniel W Mundy; Jean-Claude M Rwigema; Lisa A McGee; Samir H Patel; David M Routman; Scott C Lester; Michelle A Neben-Wittich; Yolanda I Garces; Daniel J Ma; Robert L Foote Journal: Int J Part Ther Date: 2021-06-25